Mounjaro 7.5 MG/0.5 ML pen 0.5ML
Ended Awarded
- Contract number
- SPE2DB26FATZA
- Awardee
-
DMS Pharmaceutical Group Inc. UEI PX72BSBQTKJ3
- Awarding agency
-
Defense Logistics Agency
Department of Defense
- Obligated
- $5,737
Award facts
- Contract value 100% obligated
- $5,736.88 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 424210 Drugs and Druggists' Sundries Merchant Wholesalers
- PSC
- 6505 Drugs And Biologicals
- Set-aside
- No set-aside
- Competition
- Full and Open Competition Negotiated Proposal / Quote
- Pricing
- Firm Fixed Price
- Place of performance
- Conshohocken, PA 19428, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Logistics Agency awarded a firm fixed-price delivery order valued at $5,736.88 to DMS Pharmaceutical Group Inc., a woman-owned small business pharmaceutical wholesaler, for the supply of Mounjaro 7.5 mg/0.5 mL pens on October 24, 2025. The delivery order carries an ultimate completion date of October 27, 2025, with performance to take place in Conshohocken, Pennsylvania. This award was issued without a set-aside designation, reflecting DMS Pharmaceutical Group's competitive capability in unrestricted federal procurement. The company, headquartered in Park Ridge, Illinois, and registered in the System for Award Management since 2001, specializes in distributing comprehensive pharmaceutical products and medical consumables to federal agencies, particularly the Department of Defense.
This delivery order is issued under DMS Pharmaceutical Group's Indefinite Delivery Contract with the Defense Logistics Agency's Pharmaceutical Prime Vendor Global Program Generation V (PPV-G GEN V) initiative, a $30.3 billion acquisition strategy designed to support recurring medical supply needs of military healthcare facilities worldwide. The underlying IDC, designated SPE2DR and valued at $499.999 billion, was awarded on November 13, 2025, with a completion date of December 31, 2036, and establishes DMS Pharmaceutical Group as a regional prime vendor contractor authorized to supply branded and generic prescription drugs, over-the-counter medications, biologics, and medical consumables to support Department of Defense healthcare operations globally.
Quick answers
Who was awarded contract SPE2DB26FATZA?
SPE2DB26FATZA was awarded to DMS Pharmaceutical Group Inc. by Defense Logistics Agency (Department of Defense) on October 24, 2025.
How much is contract SPE2DB26FATZA worth?
The government has obligated $5,737 on SPE2DB26FATZA.
Is contract SPE2DB26FATZA an order under another contract?
Yes. SPE2DB26FATZA is a delivery order under SPE2DB24D2106, an indefinite delivery contract.
Was contract SPE2DB26FATZA competed?
The extent of competition for SPE2DB26FATZA was full and open competition.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award